Skip to main content
. 2018 Nov 11;8(2):e1528411. doi: 10.1080/2162402X.2018.1528411

Figure 6.

Figure 6.

Subgroup analysis to estimate the benefits of PFS from adjuvant CIT. CIT significantly prolonged the PFS of EOC patients with residual tumors of no less than 1 cm. Patients with residual tumor ≥ 1 cm (A, n = 95) or residual tumor < 1 cm (B, n = 403) were divided and were analyzed. The PFS rate was evaluated by the Kaplan–Meier method and compared by the stratified log-rank test.